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United Nations Children’s Fund (UNICEF)/United Nations Development Programme (UNDP)/
World Bank/World Health Organization (WHO) implemented the Training in Tropical Diseases 
(TDR) program with excellent results; however, due to current challenges, this active program 
requires new and innovative solutions. Nowadays, Aedes aegyptis-borne diseases can be added 
among neglected diseases. Surveillance and control must be considered owing to a great risk of 
infection with dengue, chikungunya and zika viruses. Although investigations on several vaccines 
are in progress, new insights in term of development of drugs that evade from resistance are of 
paramount importance. Nanobiotechnology appears as one of the most innovative strategy in the 
search of new uses for old pharmaceuticals or in the development of innovative and intelligent 
nanomedicines for neglected diseases. Liposomes, solid lipid nanoparticles, nanoemulsions, 
polymeric nanoparticles, metallic nanoparticles, quantum dots, carbon dots and carbon nanotubes 
were the focus of the current advances. In this direction, we have focused this overview on new 
advances in diagnostic assays as nanobiosensors, antivirus and nanoinsecticides on Aedes aegyptis 
control.
Keywords: Aedes aegypti, mosquitoes, nanostructures, nanobiotechnology, antiviral, 
nanobiosensors, nanoinsecticides
1. Introduction
The Training in Tropical Diseases (TDR) program, 
approaches and contributions to drug discovery research 
and development (R&D) and the optimization of known 
treatments against infectious diseases of poor people were 
discussed.1,2 The current challenges are completely different 
from those at TDR’s beginning. Now, there are different 
players and more funding than before, and the primarily 
public or nonprofit organization, researching new drugs and 
diagnostics, but they still requires a strong coordination to 
optimize resources. The facts from the literature showed 
that this active environment needs new and innovative 
solutions.1
In our opinion, the most innovative strategy at this 
time should be the use of nanotechnology in the search 
of new uses for old pharmaceuticals or the development 
of innovative and intelligent nanomedicines for neglected 
diseases.2,3 
Among neglected diseases, one of most currently 
importance is the infection through Aedes aegypti and 
Ae. albopictus-borne and, the surveillance and control must 
be considered due to a great risk of infection with dengue, 
chikungunya, zika and also with yellow fever viruses. The 
principal vectors of dengue (DENV-1, DENV-2, DENV-3 
and DENV-4), chikungunya (CHIKV), yellow fever (YFV) 
and zika (ZIKV) viruses, transmitted by Ae. aegypti and 
Ae. albopictus, are now under the concern of Center of 
Diseases Control and Prevention (CDC),4 USA, and by 
Brazilian Government.5
Dengue virus (DV) infection generates a spectrum 
of diseases, from asymptomatic, or a flu-like mild 
undifferentiated fever, to classic dengue fever (DF) or to DF 
with hemorrhagic signs. Many other diseases can mimic DV 
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infection (e.g., influenza, typhoid fever, leptospirosis and 
measles), or non-specific viral syndrome, so diagnosis of 
DF, therefore, can be made only by specific laboratory test.6
DV infection by mosquitoes affects 2.5 billion people 
in tropical and sub-tropical regions of the world. DV is 
a member of the Flaviviridae family and is transmitted 
to humans by females of the genus Aedes, especially 
Ae. aegypti or Ae. albopictus.7
The dengue treatment is preventive and supportive 
care. The treatment of DV infection with small interfering 
RNA (siRNA) has been shown to be effective against DV 
replication.8 However, some studies showed that antivirals 
could be interesting in the future. Deoxynojirimycin and 
its N-alkylated derivatives (iminosugars) can be effective 
against DV infection by targeting host cellular factors that 
are required for viral morphogenesis.9 Flavonoids, fisetin, 
quercetin and baicalein, also exhibited anti-dengue virus 
activities (Figure 1).10
The first major success of the sterile insect technique 
was achieved against Culex quinquefasciatus in 
Myanmar in 1967 and efforts were being made against 
Culex quinquefasciatus and Ae. aegypti in India in 1967 
and, recently in Brazil.5,11 Another strategy was used in 
2000 by means of bacterium Wolbachia pipientis into 
Aedes aegypti populations for dengue control with a 50% 
reduction in the lifespan of adult female mosquito.12
Although several vaccine candidates are in advanced 
stages of development, no licensed dengue vaccine is 
available yet, then, new insights in term of development of 
drug that evade resistance from resistance are of paramount 
importance. 
2. Nanotechnology Presence on Dengue Virus 
and Other Viruses
During the last decades, the eradication of viral infections 
has still been a challenge in the medical field due to not only 
the problem of the spread, but also to their ability to evolve by 
genetic mutations, making them a real nightmare in health. In 
particular, dengue virus possesses four distinct serotypes, but 
closely related ones that the viral attack may cause a spectrum 
of illnesses, as discussed above. If subsequent infections by 
other serotypes are produced, there is an increase in the risk 
of developing severe dengue infection.6
Once there is no approved vaccine or antiviral 
agents against dengue virus, this opens the door for the 
design of new strategies to combat the infection, and 
nanobiotechnology appears to be a new feasible alternative. 
Nanobiotechnology is one of the most promising area 
that could be important in all of these diseases, including 
cancer13,14 and antibacterial agents.15
2.1. Nanobiosensors
Nowadays, the only therapy against dengue is 
prevention and palliative care, as mentioned before. For 
Figure 1. Chemical structures of products against dengue virus.
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these reasons, there is a need for the development of new, 
rapid and specific diagnostic systems to be useful tools for 
early detection of the infection, at its initial stages. Some 
nanodiagnostic tools are based on nanomaterials such as 
liposomes, nanopores and nanowires, which are coupled to 
conventional methods such as fluorescence, potentiometry 
and voltammetry.16 Most of them include enzyme-linked 
immunosorbent assay (ELISA) and reverse transcriptase 
polymerase chain reaction. Although these systems give 
rapid diagnostic information and use of inexpensive 
materials, they are currently unavailable or are scarce for 
clinical practice.17
A nanobiosensor was developed by the use of an optical 
membrane-based DNA/RNA hybridization system utilizing 
a liposome amplification, which allows the detection of a 
genomic sequence in patient blood samples (e.g., generic 
and serotype-specific synthetic dengue sequences, for 
serotypes 1-4). The method uses a biotinylated DNA 
capture probe immobilized on a streptavidin-capped 
polyethersulfone membrane, in addition to a generic 
DNA reporter probe bound to the outer surface of 
dye-encapsulating liposomes. While nonspecific RNA 
molecule generates no signal, generic sequence added to 
the dengue RNA for the amplification step is hybridized 
and the signal is turned on. This nanobiosensor showed 
an excellent correlation in the detection and was mobile, 
inexpensive and easy to use (Figure 2).18 
Another strategy in diagnostics proposes the use of 
silicon nanowire (SiNW)-based sensor for detection of 
products from DEN-2 genes after reverse transcription-
polymerase chain reaction (RT-PCR) by hybridization with 
a specific peptide nucleic acid (PNA) attached covalently 
to the SiNW surface. The positive sign was demonstrated 
by measuring the resistance change of the SiNW before 
and after hybridization.19
More recently, gold nanoparticles (NP) have been 
used for extremely sensitive and fast detection of dengue 
infection. A diagnostic device was developed for serum 
detection of antigens from a non-structural protein 
(NS1) responsible for dengue virus pathogenicity, using 
an immunoassay with gold nanoparticles conjugated to 
antibodies against NS1.20 Jahanshahi et al.21 reported a 
method based on surface plasmon resonance (SPR) for 
detection of anti-dengue virus in human serum in less than 
10 min. The DEN-1, DEN-2, DEN-3 and DEN-4 serotypes 
were immobilized onto the biochip surface that consists 
of a gold coating on glass accompanied by nanoparticles 
and immobilized antigens. Other work22 has proposed the 
detection of dengue-specific immunoglobulins (IgGs) in 
salivary fluids by piling flow immunoassay, in which the 
liquid conjugate was constructed of G protein bound to 
40-nm gold nanoparticles. The important aspect in this 
assay was that the IgG detection lies in distinguishing 
primary and secondary dengue infection since IgGs are 
specifically present in second episodes (Table 1).22 The 
developed nano-diagnostic systems can be extrapolated 
for the detection of other viral diseases. 
An immunosensor for NS1 of the dengue virus based 
on carbon nanotube-screen printed electrodes (CNT-SPE) 
was successfully developed. A homogeneous mixture 
containing carboxylated carbon nanotubes was dispersed 
in carbon ink to prepare a screen printed working electrode 
or also using a poly(allylamine) as support associated 
to carbon nanotubes. These development and approach 
represent a great potential value for use in epidemic 
situations and can facilitate the early screening of patients 
in acute phase of dengue virus.23,24
2.2. Antiviral drugs
Some studies have shown that antivirals could be an 
interesting trend in the coming future.9,10,25 Nevertheless, 
these types of compounds commonly show a low 
bioavailability, especially for therapeutic uses, the reason 
why several strategies to overcome this limitation focus 
on the use of a wide variety of nanocarriers, including 
liposomes, solid lipid nanoparticles, nanoemulsions and 
nanocrystals, or polymeric nanoparticles, among others.26
Liposomal formulations have shown interesting 
properties in terms of the effective antiviral dose, decreasing 
the toxic concentrations and enhancing the retention 
time of the drug in blood circulation (due to pegylation). 
Experiments in vivo demonstrated that the delivery 
of iminosugars (all deoxynojirimycin derivatives) via 
Figure 2. Biosensor for dengue virus detection: DNA capture probe is 
immobilized on a polyethersulfone membrane; DNA reporter probe is 
coupled to the liposome surface. When a specific dengue virus RNA is 
present (a), a sandwich is formed between capture probe, mRNA, and 
reporter probe; thus, liposomes are captured in the capture/detection zone. 
It is shown that liposomes are not captured in the detection zone when a 
nonspecific RNA molecule is present (b); in this case, no signal will be 
shown in the detection zone (adapted from reference 18).
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polyunsaturated ER-targeting liposomes (PERLs) increased 
the survival rate and prevented viral accumulation in organs 
and serum. In comparison to the administration of free 
iminosugars, liposomes only needed a 3-log lower dose to 
achieve survival of the animals. In addition, the formulation 
exhibited a greater in vitro potency against dengue virus 
by inhibiting of both the number of infected cells and the 
release of infectious viral particles induced by primary 
human monocyte-derived macrophages.27 
More interesting is the extrapolation of the technique 
to treat infections with other related viruses. The ability 
of PERLs to produce a cholesterol-lowering effect has a 
positive impact in the inhibition of virus replication, and 
antiviral activities were observed not only for dengue virus 
but also hepatitis B virus (HBV), hepatitis C virus (HCV) 
and human immunodeficiency virus type 1 (HIV-1).28,29 
Clayton et al.30 designed pegylated liposomes with the 
surface covered by labeled ligands from the Fab fragment of 
anti-HIV-gp120 monoclonal antibody (F105), and assessed 
the encapsulation of a novel HIV-1 protease inhibitor. They 
showed that immunoliposomes were effective in targeting 
and internalization into HIV-1-infected cells, delivering 
and accumulating the protease inhibitor in the cytoplasm. 
These results highlight the potential of liposomal carriers as 
vehicles for antivirals and the possibility to transport other 
cytotoxic drugs for a wide array of viruses.
Other studies have considered the development of 
solid lipid nanoparticles (SLNs) and nanostructured lipid 
carriers (NLCs) as possible matrices for the encapsulation 
of antivirals against dengue virus. Baicalein, a well-known 
flavonoid with antiviral activity, was encapsulated into SLN 
at 60.73% by the solvent injection method and showed 
a controlled release profile.31 In a similar way, baicalein 
was incorporated into 100-nm tocol NLCs for intravenous 
administration, resulting in higher plasma levels and a 
longer half-life than with free antiviral.32 Another successful 
application of SLNs was the improvement in the poor oral 
availability of lopinavir (antiviral for HIV) by encapsulation 
in glyceryl behenate-based SLNs for delivery targeted to 
intestinal lymphatic vessels.33
Nanoemulsions from essential oils are also effective 
carriers for antiviral substances acting on vector-borne 
diseases.34,35 
Several polymers such as poly(lactide-co-glycolide) 
(PLGA), poly(D,L-lactic acid) (PLA), polyglycolide, 
polycaprolactone (PCL), poly(D,L-lactide), chitosan 
and PLGA-polyethylene glycol (PEG) were developed 
for passive and ligand-targeted delivery of therapeutic 
drugs.36,37 In particular, it was observed that carriers 
for antiviral drugs exert the antiviral activity of the 
encapsulated molecules, indicating that direct interaction 
between the nanoparticles and the virus may inhibit 
viral attachment to cells.38 A tetravalent dengue system, 
composed of bovine serum albumin (BSA) nanoparticles, 
was evaluated in a murine model.39 BSA-NPs could absorb 
the four serotypes of dengue in their inactive form and, 
Table 1. Nanodispositives in biosensing
Nanodevice Description Use Reference
Membrane/liposome
nanobiosensor composed of biotinylated DNA capture probe 
immobilized on a streptavidin-coated polyethersulfone 
membrane, in addition to a generic DNA reporter probe 
coupled to the outer surface of dye encapsulating liposomes
detection of dengue genomic 
sequences (for serotypes 1-4) in 
blood samples of patients
18
Silicon nanowire
silicon nanowire (SiNW) with a specific peptide nucleic 
acid covalently attached onto surface, which hybridizes with 
products of DEN-2 genes
detection of products from DEN-2 
genes after reverse-transcription-
polymerase chain reaction 
(RT-PCR)
19
Gold nanoparticle
nano-gold particles conjugated to antibodies from a non-
structural protein (NS1) responsible for dengue virus 
pathogenicity NS1
serum detection of antigens from a 
NS1 protein 20
a biochip with the DEN-1, DEN-2, DEN-3 and DEN-4 
serotypes immobilized onto the surface, made of a gold 
coating on glass accompanied by nanoparticles and the 
immobilized antigens
detection of anti-dengue virus in 
human serum in less than 10 min, 
by the surface plasmon resonance
21
40 nm in size gold nanoparticles conjugated to G protein
detection of dengue-specific 
immunoglobulins (IgGs) in 
salivary fluids by stacking flow 
immunoassay
22
Carbon nanotube-screen 
printed electrode (CNT-SPE)
an immunosensor for the non-structural protein 1 (NS1) 
of the dengue virus
facilitate the early screening of 
patients in acute phase of dengue 
virus
23, 24
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after administration, an induction of anti-DENV IgG 
antibodies was produced (Figure 3).
Other nanoparticles composed of chitosan/bacillus 
Calmette-Guerin (BCG) cell wall components were able 
to encapsulate a novel dengue nanovaccine (produced 
by UV inactivation of DENV-2) and showed interesting 
immunogenic properties in a Swiss albino mouse model 
by generation of humoral and cellular immune responses.40 
Polymeric nanoparticles of polylactic acid (PLA) and 
methacrylic acid copolymers were designed to entrap the 
peptidomimetic compound CGP 57813, a potent HIV-1 
protease inhibitor. Due to its high lipophilicity, it showed 
a poor bioavailability. While PLA nanoparticles (PLA 
NPs) showed an increase of at least two times in the 
plasma concentration-time curve (area) after intravenous 
injection in mice, no sufficient plasma level was detected 
after oral administration, and only the methacrylic acid 
copolymer nanoparticles provided reasonable values.41 
However, in other studies, PLA NPs were demonstrated to 
be feasible drug delivery carriers to enhance tissue uptake 
and the targeting of other macromolecules with anti-HIV-1 
activity.42 Also, PLGA nanoparticles have shown interesting 
applications as vaccine-delivery vehicles for treatment of 
viral infections.43
Polyhexylcyanoacrylate nanoparticles were loaded with 
saquinavir (another HIV protease inhibitor) or zalcitabine 
(a nucleoside analog) and tested under in vitro conditions 
in primary human monocytes/macrophages. A dose-
dependent reduction in HIV type 1 antigen was observed 
for both types of nanoparticles.44 Hexylcyanoacrylate 
nanoparticles were developed as a colloidal azidothymidine 
(AZT) carrier for specific targeting of the antiviral drug 
to reticuloendothelial cells by oral administration in HIV 
patients.45 By modifying this kind of nanoparticles through 
the coating with polysorbate 80, it was possible to change 
the body distribution of AZT after intravenous injection in 
rats, with a higher concentration of the drug in the brain. 
Although the drug was bound to the nanoparticles, its 
efficacy was not reduced.45 AZT was also encapsulated in 
polybutylcyanoacrylate (PBCA) and methylmethacrylate-
sulfopropylmethacrylate (MMA-SPM) nanoparticles, 
and the study of their permeability across the blood-brain 
barrier revealed an enhancement in their permeability with 
a reduction in nanoparticles size.46 Furthermore, AZT- 
loaded poly-(isohexylcyanoacrylate) nanospheres displayed 
promising features to target the antiviral to the epithelium 
of the intestine and gut-associated lymphoid tissues, which 
are the main reservoirs of HIV in the gastrointestinal 
(GI) tract.47 The preparation of pH sensitive NPs was an 
interesting alternative to improve the bioavailability of HIV-1 
protease inhibitor with a very low water-solubility. In this 
sense, nanoparticles made of the poly(methacrylic acid-co-
ethylacrylate) copolymer Eudragit® L100-55 were orally 
administered to dogs of beagle breed and led to an increase in 
plasma concentrations due to a specific release of the antiviral 
near its absorption site.48 Shah and Amiji49 demonstrated that 
Figure 3. Nanosystems for treatment of dengue: (a) SEM micrograph of silver NPs adsorbed on fungal mycelial filaments of C. lunatus, which showed 
larvicidal activity against Ae. aegypti (adapted from reference 60); (b) BSA nanoparticles observe at SEM (up) with the ability of adsorb inactivated DENV 
onto the surface. The presence of viral particles was determined by ELISA assays using monoclonal antibodies against DENV-1, 2, 3 or 4 (down) (adapted 
from reference 39 (©Silva et al.; licensee BioMed Central Ltd., 2012)).
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poly(ethylene oxide)-modified poly(epsilon-caprolactone) 
(PEO-PCL) nanoparticles were a feasible vehicle for the 
intracellular delivery of saquinavir. PEO-PCL nanoparticles 
exhibited spherical shape and uniform size distribution 
around 200 nm. Their uptake by THP-1 (human leukemic) 
monocyte/macrophage (Mo/Mac) cells indicated a 
significantly higher incorporation of the drug in comparison 
with aqueous solution. 
It is important to mention that the surface of the 
described nanoparticles can be tailored to modify the 
biodistribution of the antiviral to target specific organs 
and tissues or, with more precision, to deliver the drug 
to a particular cell type by attachment of ligands that 
recognize cell surface receptors.50 All of these facts are 
easily extrapolated to Ae. aegypti virus.
Although there are currently few reports in the literature, 
the first products are appearing on the market and a new 
tendency is indicating that nanocrystals could be a possible 
delivery system to improve the bioavailability of antiviral 
drugs.51,52 For example, pure quercetin, a flavonoid with 
anti-dengue virus activity, showed a limited in vivo efficacy 
because of its low solubility and reduced absorption at 
the intestine level. However, the synthesis of four types 
of co-crystals led to an improvement in physicochemical 
and pharmacokinetic characteristics in comparison with 
free quercetin.53 Other reports have described the use of 
cellulose nanocrystals (CNCs) as viral inhibitors. The 
first approach was carried out with unmodified CNCs 
derived from tunicates in a single model, and a decrease 
in phage infection of host E. coli was observed.54 In the 
next step, the modification of CNCs by surface attachment 
of tyrosine sulfate mimetic ligands (multivalent displays) 
resulted in the inhibition of alphavirus infectivity in Vero 
cells. Considering these results and the chemical structure 
of other known polyanionic inhibitors, the possibility to 
using CNCs for inhibition of other viruses (e.g., HIV and 
herpes simplex viruses) should be explored.55 A recent 
work also reported the production of nanocrystals of a 
reverse transcriptase inhibitor from HIV-1 virus (CSIC) 
by a three-phase nanoparticle engineering technology for 
intravaginal delivery.56
During the last decade, investigations have shown 
the potential of metal nanoparticles for treatment of viral 
infections. The interaction of silver and gold nanoparticles 
with proteins is under exploration, and the mechanism of 
antiviral activity is not well established.57 However, it was 
observed that gold nanoparticles conjugated to fragments 
of the HIV inhibitor TAK-779 (named SDC-1721) showed 
an excellent antiviral effect, while free SDC-1721 had no 
activity. This means that gold nanoparticles are able to 
convert inactive molecules into potent antivirals.58 On the 
other hand, silver nanoparticles have also shown interesting 
properties by interacting with HIV virus and thereby 
preventing their binding to host cells, as long as they are 
in the range of 1-10 nm in size.59
2.3. Nanoinsecticide against mosquitoes
A nanoinsecticide is defined as a nanostructure 
containing a formulation that includes nanoscale elements 
with novel properties associated with some actives acting 
on insects. The benefits of this formulation are: efficiency 
due to higher surface area, sometimes higher solubility, 
higher mobility and a low toxicity, because no organic 
solvent is used related to the conventionally used in many 
pesticides. 
An important group of nanoinsecticides is found with a 
nanoemulsion containing Rosmarinus officinalis essential 
oil (250 ppm), and its larvicidal activity against Ae. aegypti 
larvae, showed a mortality levels of 80 ± 10 and 90 ± 10% 
after 24 and 48 h, respectively.35 
The green synthesis of metal nanoparticles has been 
proposed as an alternative to chemical methods, particularly 
through the use of fungi, since that the benign environment 
and renewable source of fungi act as reducing agents in 
the preparation of metal nanoparticles. These kinds of 
nanoparticles have exhibited efficacy against mosquito 
larvae (e.g., Aedes, Culex and Anopheles).60-65 In addition, 
leaf extracts from plants have been used for silver 
nanoparticle production and have become an eco-friendly 
alternative for adulticidal activity against filarial, dengue 
and malaria vector mosquitoes (Table 2).66-69
An interesting review on biogenic silver nanoparticles 
against mosquitoes was recently reported.70,71
Biogenic silver nanoparticles acting on Aedes aegypti 
and Culex quinquefasciatus (instars IV) demonstrated 
median lethal concentrations (LC50) of  0.30 and 
0.41 μg mL-1, respectively. Adult longevity (days) in male 
and female mosquitoes exposed as larvae to 0.1 μg mL-1 
silver nanoparticles was reduced by 30%, whereas the 
number of eggs laid by females exposed as larvae to this 
concentration decreased by 36%.72
The larval susceptibility to the basil oil (mainly 
estragole) nanoemulsion against third-instar larvae of 
Ae. aegypti showed a ten-fold diluted basil oil formulation 
(standard solution of 6% basil oil), inducing 100% larval 
mortality in 15 min. Complete loss of larval viability was 
observed after an exposure period of 90 min.34 
Important results on biogenic silver nanoparticles on 
biological systems were reported.73-75 So far, mortality of 
mosquito larvae is concerned, it has been found that LC50 
as low as 0.56 ranges to 606.5 μg mL-1 and also lower than 
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those values cited.70 Ae. aegypti showed very sensitivity 
towards the mortality with biogenic silver nanoparticles 
(Table 3).66-69,76-82 Besides these actions, silver nanoparticles 
were effective against Anopheles and Culex.83-85 Against Ae. 
Albopictus, biogenic silver nanoparticles exhibited a 100% 
mortality at 5 μg mL-1 level.86 Probably the large difference 
between different sources for biogenic synthesis of silver 
nanoparticles was due to the presence of different kind of 
capped protein on the nanoparticles or due to the presence 
of different silver nanostructures (e.g., silver chloride 
nanoparticles or/and silver oxides).87
A 3 μg mL-1 dose of water soluble carbon nanoparticles 
(carbon dots) in a stagnant water pool was found as 
optimum to arrest further growth of mosquitoes beyond 
the larval stage. At this concentration, the larvae stayed in 
suspended animation for four weeks and beyond that period 
of death without any toxicity or disturbing on surrounding 
ecosystem.12 
The composite chitosan, carbon quantum dots and 
silica complexed with double-stranded RNA (dsRNA), was 
tested in order to target genes (SNF7 and SRC) to control 
Ae. aegyptis larvae. The result showed that knockdown 
efficiency correlated with dsRNA mediated larval mortality, 
being quantum dots the most efficient one and causing gene 
silencing and mortality in Ae. aegypti.88
3. Perspectives and Final Remarks
All the information discussed in this overview pointed 
out to the real potential of nanobiotechnology on virus 
inactivation and on insect control. Other important 
aspects in this overview are the safe use of nanomaterials 
that must be known through their toxicity and the effect 
in the environment, before its use. We hope this review 
encourages other researchers to do further research related 
to nanobiotechnology against Ae. aegyptis.
Table 2. Nanodispositives in treatment of dengue virus and mosquito/larvae of Aedes aegypti
Nanodevice Drug/Composition Use Reference
Liposome iminosugars/polyunsaturated ER-targeting liposomes
improvement in the effective dose of antiviral and 
enhancement of the drug retention (blood) 27
Solid lipid nanoparticle baicalein (flavonoid)/lipidic matrix controlled release of the antiviral 31
Nanostructured lipid 
carriers baicalein (flavonoid)/tocol
increase the half-life than administration of free 
antiviral 32
Nanoemulsion
essential oils (from Rosmarinus officinalis, 
Ocimum basilicum L.)/surfactants (polysorbate 20; 
Tween 20)
kill the mosquito larva of Aedes aegypti 34, 35
Polymeric NP
poly(lactide-co-glycolide) (PLGA), poly(D,L-lactic 
acid) (PLA), polyglycolide, polycaprolactone 
(PCL), poly(D,L-lactide), PLGA-polyethylene 
glycol (PEG)
NPs may inhibit the viral attachment to cells 36-38
Biopolymeric NP NPs composed of chitosan/Mycobacterium bovis Bacillus Calmette-Guerin cell wall components
development of a dengue nanovaccine (produced by 
UV inactivation of DENV-2) 40
Protein NP bovine serum albumin (BSA) NPs containing the four serotypes of dengue in their inactive form
vaccine: after administration an induction of anti-
DENV IgG antibodies is produced 39
Nanocrystal quercetin enhance the anti-dengue virus activity of the drug by increasing bioavailability 51, 53
cellulose act as viral inhibitors 54, 55
Carbon quantum dot (CQD) only CQD or complexed with dsRNA
cause gene silencing of dengue virus genes and 
mortality in Aedes aegypti. Inhibition of growth in 
mosquitoes beyond the larval stage
12, 88
Metallic NP (chemical 
synthesis)
gold NPs antiviral effect after conjugation of NPs with fragments of proteins 58
silver NPs prevention of the viral binding to host cells by interacting with virus structure 59
Metallic NP (green 
synthesis)
silver and gold NPs produced by leaf extracts from 
plants or fungi efficacy against mosquito larvae 60-69
NP: nanoparticle.
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